%PDF-1.7 % 26 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20250501120448+02'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 27 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 5 0 R 7 0 R 8 0 R 9 0 R 10 0 R 11 0 R 12 0 R 13 0 R ] /PZ 1 >> endobj 27 0 obj <> stream xZr6+Ɍ|HdwN$nȋ6` )I $,}zAzRzJZ<2A{=dn|>|9Z>vyG$s eq8ƣ goL8putu߮xo7ty]%mmx9 ^Q}1 &m6ڞ6 O;WùI`zB\mm- {GbItm-ϴJ/ x," "*wES>&)My ~‹owa^J t{yxf,AVC3&3F I|P` y MԚZSr:1tNIomǵ}Tj~nhV8Cpǰhn)M ǩ7;f:Hǰ켻_%8T5F-x[ :\KaE&)gO ExHyNE0 Ǭ n3,+E~VaIE״ ˻SWZxYr,4z첸u0w̹?;DﶼqR-D(; gb|-踆lNYI,i.+AkHabȈޚY؀_h> /Annots [ 14 0 R 15 0 R 16 0 R 17 0 R 18 0 R ] /PZ 1 >> endobj 29 0 obj <> stream x[r۶S&ɌI+I&[i4LA2Z`@Rmy^,@RU%(" ÷omlxxm[̶vÏ[] ~鈘kzbUOaGq ?_ؗzml.?FoQwԿFs`ٖ `\ y&,g?CN YNS.hgiPؓi\J%3F|jF91- x7L0~u_ +lACL9U r1T%BaJUJcG. =Ip=Zj?b;QsQd3 kLj8 <!9xD܅L)4M126 > {?ټk`*k %ny=;8q[Jk@UAaN$ KܨaR`c{1ތ˝Z ̑5ҟ`@9 QP#[繡_!=RFݑowh$uN~I,mdidE;KI w_c 5Xڦi%MQ9;tK{`_)|]ܑ幝 3)rzK.HFMXP/kMXkA˴jKhQpA5S%]\ i/!^F^Uf$ c y~Uj RQ'pJBbѼ=*bTe { ا\__䅢2bl能7M8NHXDAJ pRf3.U]WV0d`jSY9fl4ƈ3A 1SM(Luaq+\r]\hK $L(,hp4h<&.# (SzQYH-]DUE`8^SNS \Ri*Rń"bjQD""qW 8㹜 Q.'Oͼ ĭQET./̷8+|lhߤ@"*V D:dSYi?<@5Us6.u{knJ|4|iv8TqFǟPlCk2꨽/zEvв\s9_ 6Kp9x#70K="JXnf32?sDu)@LYAPgR ]qts*L>Zf(9sj1A1Ej=erֱreؘeD/`!, MPMx*ur&(>ͥz=?;|)u,+X:Py\Co_Lr7R8 NF1jֲ${3Ũ5u _Ks V֢Ew?2=ꡮK[Xr5")Ej|]f57()β.]BqbZ@A+!83hu[lY6 amv'FRoy8xxn`X;w`n%KX;m^'NÇl޹"q]{jZ7&8|\Tq&nK9W4˝!\/Y}z@x a{݌~gqF5$Gdhm߶g{&h>]2XlmkލP4"1|74"cq[ݩEW'kPAMtYt§L$2fG{uphhoN$CEslR۫)Yfyd9AwNZ896s\+&D#U\t2Ă_J&Ѥ8#$s1=W+HOPcURX4?e KP=vs$kEUГܝX@0WI6!= W3Yk_ 's` endstream endobj 30 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20250501120448+02'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 31 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R ] /PZ 1 >> endobj 31 0 obj <> stream xY]S[7}WfEҮ@44i?TG:oV^zI=ժznolf KbF,;cQ F滽#f܌Njj8jH ï/h+y{l~O]}u{O:%|jN.Ѝ ],iBZ9cM~9'6cet6 Rͩ9Yy]#@nmJ5³xIefO8 S]*F g Y󡙜ը丙fP[ZW٨9Wo9(88丶~gb^XʼKwt{HEqʸe&™&m$YC䵥jIDS*쾺v_cu}צmStlu>sE!7rAřzVV`%* Zq A1TApmCI`)\l]L8W0'*h|a,BMxWʌ!8OQ:_mLXWPɸlS50ߊ8-bwT╲c#[; Đ!8q"LF2l[rԂ> M #Pm6ZMnM1Ė9R/Td[аqv59œGDP6?ֶ8h2YxMAIx`2mR*kZQS$es897D1bqWl6z ΆhXp>HD|eRh U)"CNvq@p\DcтlE jhPO2`2.PZSU֑˱u\uZ.,֠Vs/FɆ]uC@B^Y /q5VؼP+mr`Fm9n-{'@ 1 &Vt#l#@SGO*Zp1P"h[: Z9w£RĞD+ УKYqI0m$]"#uͧHmi]]iiQ8Jk̺Y%@ܡ1"M`ۮ5`08mתb.׮ckp*FvB!FT`9PdELLݸm VF8 v.'S7gso`mr)KA 1%uˑͥ+fLAwsZX9K$cSjxd|{g^-(ksra۞BxPLt8Rsj'G\X%$o|m;rRsw7pH?ID#-W?..Y3RVmPEn. =?<:֒o?r] endstream endobj 1 0 obj << /Type /Pages /Kids [ 26 0 R 28 0 R 30 0 R ] /Count 3 >> endobj 3 0 obj <> endobj 4 0 obj <> endobj 6 0 obj <> endobj 32 0 obj <> /Resources <> /Font <> /ExtGState <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 848 >> stream xWmO0^c$H (똆AIC|J(ՠemIªل׹Gdw7>9<GkDžaW$<"H2|R(29:9$^-e>..y.Gd:|VCd` ')ɮB(TEҒ %% E֙ J,$BDO&D>MH0-6=C.h&CfR\ X+b :Nic*k+ p.}&xs|"8 n,v )W-6o=߸hNftK:M[ۀr!e\KeAky$RP<⺍pxup8>H  M{qI3_w,縲eGfNՑmna.hȓjYU,b\2OuyZ6#sC͚3gkriӲ ly#4]kDfu |w*lm O镸080iIsӵһ%7/i\XJ.̚5K5jM9aq'wqh%Q*i gyQ(p]5'CԫkSuRCln_*9{.+|FAqp-Pg*O hsRՎSJ&`1U$GBHB-K5NюG~?Rh#%SkC3a-r"7αը $O+ o endstream endobj 39 0 obj <> /Resources <> /Font <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 220 >> stream x]M0EԅIтUqEڅ̿7.:Ãۼ{?bb_"YiFgTT&IF |Sk=(PB{U!Z]?s{7mCwoTbV DH)iRHK 4 A&J0;*UaVj&T]Y-v|OɄzUx5>w I endstream endobj 38 0 obj <> endobj 37 0 obj <> endobj 44 0 obj [250 0 0 0 0 0 0 0 0 0 0 564 0 333 250 0 500 500 500 500 500 0 500 500 500 500 0 0 0 0 0 0 921 0 0 0 722 611 556 722 722 0 0 0 0 889 0 0 556 0 667 556 0 0 0 0 0 0 611 0 0 0 0 0 0 444 500 444 500 444 0 0 500 278 0 500 278 778 500 500 500 0 333 389 278 500 500 722 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 ] endobj 43 0 obj <> endobj 36 0 obj <> stream x  Om7^ Oa endstream endobj 45 0 obj <> stream x nH@o endstream endobj 35 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 34 0 obj <> stream x  Om783  endstream endobj 46 0 obj <> stream x nH@paX endstream endobj 33 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > endobj 48 0 obj [250 ] endobj 47 0 obj <> endobj 41 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 40 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > /XObject <> >> endobj 5 0 obj <> /H /I>> endobj 7 0 obj <> /H /I>> endobj 8 0 obj <> /H /I>> endobj 9 0 obj <> /H /I>> endobj 10 0 obj <> /H /I>> endobj 11 0 obj <> /H /I>> endobj 12 0 obj <> /H /I>> endobj 13 0 obj <> /H /I>> endobj 14 0 obj <> /H /I>> endobj 15 0 obj <> /H /I>> endobj 16 0 obj <> /H /I>> endobj 17 0 obj <> /H /I>> endobj 18 0 obj <> /H /I>> endobj 19 0 obj <> /H /I>> endobj 20 0 obj <> /H /I>> endobj 21 0 obj <> /H /I>> endobj 22 0 obj <> /H /I>> endobj 23 0 obj <> /H /I>> endobj 24 0 obj <> /H /I>> endobj 25 0 obj <> /H /I>> endobj 49 0 obj << /Title (Carcinoma mammario HER2 -positivo metastatico: il CHMP raccomanda l approvazione in UE di Trastuzumab Deruxtecan) /Author (Daiichi Sankyo) /Subject (Carcinoma mammario HER2 -positivo metastatico: il CHMP raccomanda l approvazione in UE di Trastuzumab Deruxtecan) /Creator (TCPDF) /Producer (TCPDF 6.8.2 \(http://www.tcpdf.org\)) /CreationDate (D:20250501120448+02'00') /ModDate (D:20250501120448+02'00') /Trapped /False >> endobj 50 0 obj << /Type /Metadata /Subtype /XML /Length 4887 >> stream application/pdf Carcinoma mammario HER2 -positivo metastatico: il CHMP raccomanda l’approvazione in UE di Trastuzumab Deruxtecan Daiichi Sankyo Carcinoma mammario HER2 -positivo metastatico: il CHMP raccomanda l’approvazione in UE di Trastuzumab Deruxtecan 2025-05-01T12:04:48+02:00 TCPDF 2025-05-01T12:04:48+02:00 2025-05-01T12:04:48+02:00 TCPDF 6.8.2 (http://www.tcpdf.org) uuid:fa9bb041-2627-b66a-1c63-65420ba4e5f4 uuid:fa9bb041-2627-b66a-1c63-65420ba4e5f4 http://ns.adobe.com/pdf/1.3/ pdf Adobe PDF Schema internal Adobe PDF Schema InstanceID URI http://ns.adobe.com/xap/1.0/mm/ xmpMM XMP Media Management Schema internal UUID based identifier for specific incarnation of a document InstanceID URI http://www.aiim.org/pdfa/ns/id/ pdfaid PDF/A ID Schema internal Part of PDF/A standard part Integer internal Amendment of PDF/A standard amd Text internal Conformance level of PDF/A standard conformance Text endstream endobj 51 0 obj << /Type /Catalog /Version /1.7 /Pages 1 0 R /Names << >> /ViewerPreferences << /Direction /L2R >> /PageLayout /SinglePage /PageMode /UseNone /OpenAction [26 0 R /FitH null] /Metadata 50 0 R >> endobj xref 0 52 0000000000 65535 f 0000007024 00000 n 0000044243 00000 n 0000007098 00000 n 0000007204 00000 n 0000044393 00000 n 0000007315 00000 n 0000044653 00000 n 0000044904 00000 n 0000045159 00000 n 0000045414 00000 n 0000045670 00000 n 0000045960 00000 n 0000046250 00000 n 0000046539 00000 n 0000046747 00000 n 0000046955 00000 n 0000047163 00000 n 0000047390 00000 n 0000047647 00000 n 0000047905 00000 n 0000048163 00000 n 0000048421 00000 n 0000048706 00000 n 0000048990 00000 n 0000049377 00000 n 0000000015 00000 n 0000000531 00000 n 0000002117 00000 n 0000002616 00000 n 0000004764 00000 n 0000005277 00000 n 0000007429 00000 n 0000019113 00000 n 0000018320 00000 n 0000010650 00000 n 0000010090 00000 n 0000009237 00000 n 0000009181 00000 n 0000008649 00000 n 0000035743 00000 n 0000028073 00000 n 0000027613 00000 n 0000009838 00000 n 0000009423 00000 n 0000010397 00000 n 0000018801 00000 n 0000027821 00000 n 0000027798 00000 n 0000049595 00000 n 0000050332 00000 n 0000055302 00000 n trailer << /Size 52 /Root 51 0 R /Info 49 0 R /ID [ ] >> startxref 55512 %%EOF

Carcinoma mammario HER2 -positivo metastatico: il CHMP raccomanda l’approvazione in UE di Trastuzumab Deruxtecan

Il CHMP esprime parere positivo per l’approvazione di trastuzumab deruxtecan, l’anticorpo monoclonale coniugato di Daiichi Sankyo e AstraZeneca. La raccomandazione si basa sui risultati positivi di DESTINY-Breast01, il trial che ha dimostrato risposte durature in pazienti con carcinoma mammario metastatico HER2-positivo precedentemente trattato.

Tokyo, Monaco, 11 dicembre 2020 – il Comitato per i Medicinali per Uso Umano (CHMP) dell’Agenzia Europea del Farmaco (EMA) ha espresso parere positivo per l’autorizzazione all’immissione in commercio condizionata in UE di trastuzumab deruxtecan, l’anticorpo monoclonale coniugato di Daiichi Sankyo e AstraZeneca, come monoterapia per il trattamento di pazienti adulti con carcinoma mammario HER2-positivo metastatico che hanno già ricevuto duo o più terapie anti-HER2.

Al termine della procedura di valutazione accelerata richiesta dalle due aziende farmaceutiche, il CHMP ha espresso il suo parere positivo basandosi sui risultati dello studio registrativo di fase II DESTINY-Breast01, pubblicati sul The New England Journal of Medicine, e su quelli dello studio di fase I pubblicati su The Lancet Oncology. Nel DESTINY-Breast01, l’anticorpo monoclonale coniugato trastuzumab deruxtecan ha dimostrato un'attività clinicamente significativa e duratura in pazienti che avevano già ricevuto due o più precedenti terapie anti-HER2. Il profilo di sicurezza e tollerabilità di trastuzumab deruxtecan osservato nello studio DESTINY-Breast01 era coerente con quello osservato nello studio di fase I.

L'opinione positiva del CHMP sarà ora riesaminata dalla Commissione europea, l’organo che ha l'autorità di approvare l'immissione in commercio dei farmaci all’interno dell'Unione Europea.

In Europa, ogni anno vengono diagnosticati circa 520.000 casi di carcinoma mammario femminile, di questi circa 1 su 5 risulta HER2-positivo.[i],[ii],[iii] Responsabile di oltre 137.000 decessi all'anno, questa malattia ha un impatto significativo.1

Durante il San Antonio Breast Cancer Symposium (SABCS) 2020, Daiichi Sankyo e AstraZeneca hanno presentato un’analisi aggiornata da DESTINY-Breast01, che conferma l'efficacia duratura e il profilo di sicurezza e tollerabilità a lungo termine di trastuzumab deruxtecan.

"Siamo incoraggiati dal parere positivo del CHMP, dato il significativo bisogno insoddisfatto di pazienti con carcinoma mammario metastatico HER2-positivo. -  Ha dichiarato Gilles Gallant, BPharm, PhD, FOPQ, Vicepresidente senior, Responsabile globale dello Sviluppo oncologico, del reparto Ricerca e sviluppo di Daiichi Sankyo - Trastuzumab deruxtecan è già disponibile per le pazienti con carcinoma mammario metastatico HER2 positivo negli Stati Uniti e in Giappone, e ora siamo un passo più vicini a rendere disponibile questa importante terapia innovativa anche alle pazienti europee".

"La durata della risposta tumorale senza precedenti dimostrata nello studio DESTINY-Breast01, non era mai stata osservata in questa tipologia di pazienti. - Ha commentato José Baselga, MD, PhD, Vicepresidente esecutivo del reparto Ricerca e sviluppo in oncologia di AstraZeneca -  "Se approvato dalla Commissione europea, gli oncologi in Europa avranno una nuova importante opzione terapeutica per i pazienti con carcinoma mammario metastatico HER2-positivo precedentemente trattato".

Riferimenti

[I] GLOBOCAN 2018 Graph production: IARC. World Health Organization. November 2019.

[II] Tandon A, et al. J Clin Oncol. 1989;7(8):1120-8.

[III] Sledge G, et al. J Clin Oncol. 2014;32(19):1979-1986

[IV] Iqbal N, et al. Mol Biol Int. 2014;852748.

[V] de Melo Gagliato D, et al. Oncotarget. 2016;7(39):64431-46.

[VI] The National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 3.2020. Breast Cancer. June 2020.